LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Verition Fund Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

Evommune, Inc IPO will take place November, 06 on the NYSE exchange under the ticker EVMN. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider lock-up period of 180 days ending on May 05, 2026. See also: Benzinga IPO Calendar About Evommune, Inc Evommune is a clinical-stage biotechnology company developing innovative...

BillionToOne, Inc (NASDAQ:BLLN) IPO will take place November, 06 on the NASDAQ exchange under the ticker BLLN. The company is offering shares at an expected price between $49.00 and $55.00 per share with an insider lock-up period of 180 days ending on May 05, 2026. See also: Benzinga IPO Calendar About BillionToOne, Inc BillionToOne is transforming healthcare by redefining molecular...